Trial Profile
A Phase 1 Study of Dabrafenib in Combination with Lapatinib in BRAF Mutant Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Lapatinib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Adverse reactions
- 02 Dec 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2024.
- 02 Dec 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2024.
- 11 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.